MAEL

MAEL is a germ-cell-enriched protein that functions in transposable element silencing, piRNA pathway biology, and gametogenesis, while also serving as an oncogenic effector in multiple cancer types. In germ cells, MAEL localizes to nuage compartments and mitochondria, co-localizes with the piRNA pathway effector MIWI, directly binds GPX4 and UBL4B, and is required for mitochondrial function, ATP production, and early oogenesis (PMID:23412502, PMID:36779514, PMID:23410657). MAEL expression is controlled by promoter CpG island methylation, and its silencing de-represses LINE-1 retrotransposons, linking MAEL to transposon control in both germ cells and cancer (PMID:29095993, PMID:27926513). In cancer cells, MAEL scaffolds chaperone-mediated autophagy of Krebs cycle enzymes citrate synthase and fumarate hydratase (via its MAEL and HMG domains bridging these substrates to HSPA8) to promote aerobic glycolysis, drives lysosomal degradation of the phosphatase ILKAP to hyperactivate p38/CHK1/RSK2 signaling, interacts with Snail to repress E-cadherin and induce EMT, and transactivates PTGS2 to activate AKT/NF-κB/STAT3 signaling (PMID:36866961, PMID:29371914, PMID:27537253, PMID:35740546).

1. 2009 Medium

   Establishing that MAEL expression is epigenetically regulated resolved how a germline gene becomes silenced or activated in somatic/cancer contexts, revealing CpG island methylation as the principal on/off switch.

   Evidence Luciferase reporter mapping of the MAEL promoter CpG island and 5-Aza-dC demethylation rescue in human cells

   PMID:19693694

   Open questions at the time

   • Factors that establish or maintain MAEL promoter methylation in vivo are not identified
   • Whether methylation-dependent regulation operates equivalently in germ cells versus cancer cells is untested
2. 2013 Medium

   Subcellular mapping of MAEL to nuage and non-nuage compartments in spermatocytes, together with MIWI co-localization, positioned MAEL as a component of the piRNA/transposon-silencing machinery in mammalian male germ cells.

   Evidence Immunofluorescence and immunoelectron microscopy in rat testis sections

   PMID:23412502

   Open questions at the time

   • Direct biochemical interaction between MAEL and MIWI was not demonstrated
   • Whether MAEL functions in piRNA biogenesis versus downstream effector silencing remains unresolved
3. 2013 Medium

   Demonstrating that MAEL is required for early oogenesis extended its functional role beyond spermatogenesis to female germ-cell development.

   Evidence siRNA knockdown in mouse fetal ovary explants and embryonic stem cell-to-germ-cell differentiation assay

   PMID:23410657

   Open questions at the time

   • The molecular targets of MAEL during oocyte differentiation are unknown
   • No conditional knockout confirms this phenotype in vivo
4. 2013 Medium

   Identification of MAEL interactions with stress granule components (PABPC1, YBX1, KHSRP, EIF4A1, and others) in cancer cells revealed a potential somatic role in mRNA regulation and miRNA-mediated silencing beyond the germline piRNA pathway.

   Evidence Anti-tag co-IP followed by nano-LC-MS/MS and immunofluorescence co-localization with PABPC1 under oxidative stress in cancer cells

   PMID:24189637

   Open questions at the time

   • Functional consequence of MAEL–stress granule association for mRNA fate is not established
   • RNA-binding activity of MAEL itself was not tested
5. 2016 Medium

   The finding that MAEL interacts with Snail to repress the E-cadherin promoter provided the first direct mechanistic link between MAEL and epithelial-mesenchymal transition in cancer.

   Evidence Co-immunoprecipitation, confocal co-localization, and E-cadherin promoter luciferase reporter assay in colon cancer cells, with in vivo xenograft validation

   PMID:27537253

   Open questions at the time

   • Whether MAEL binds DNA directly at the E-cadherin promoter or acts solely through Snail scaffolding is unknown
   • Structural basis of the MAEL–Snail interaction is not defined
6. 2017 Medium

   Two studies converged to show that MAEL controls transposable element activity in both somatic and cancer contexts: targeted promoter methylation de-repressed LINE-1, and MAEL depletion in cancer cells activated retrotransposons and ATM-dependent DNA damage, establishing transposon silencing as a core MAEL function outside the germline.

   Evidence Targeted MAEL promoter methylation with L1 expression readout; siRNA knockdown with retrotransposon assay, ATM inhibitor epistasis, ROS/apoptosis/senescence assays, Myc/Ras transformation assay

   PMID:27926513 PMID:29095993

   Open questions at the time

   • The molecular mechanism by which MAEL silences transposons in somatic cells (piRNA-dependent or independent) is not resolved
   • Whether retrotransposon de-repression is the primary cause of ATM activation upon MAEL loss or a parallel effect is unclear
7. 2017 Medium

   Showing that MAEL drives lysosomal degradation of the phosphatase ILKAP, with consequent hyperphosphorylation of p38, CHK1, and RSK2, established a protein-degradation-based oncogenic mechanism distinct from transposon silencing.

   Evidence siRNA/overexpression, lysosome inhibitor rescue, phospho-substrate western blots, adenoviral ILKAP rescue in gastric cancer xenografts

   PMID:29371914

   Open questions at the time

   • How MAEL targets ILKAP specifically to lysosomes is unknown
   • Whether the MAEL–ILKAP axis operates through chaperone-mediated autophagy (as later shown for CS/FH) has not been tested
8. 2022 Medium

   Identifying PTGS2 as a transcriptional target of MAEL that activates AKT/NF-κB/STAT3 signaling added a transcription-level oncogenic axis to MAEL's repertoire in hepatocellular carcinoma.

   Evidence MAEL knockout, transcriptional profiling, PTGS2 overexpression rescue, and western blot pathway analysis in HCC cells

   PMID:35740546

   Open questions at the time

   • Whether MAEL directly binds the PTGS2 promoter or acts through an intermediary transcription factor is not determined
   • Generalizability to other cancer types is untested
9. 2023 High

   Domain-resolved mapping revealed that MAEL scaffolds chaperone-mediated autophagy of Krebs cycle enzymes: the MAEL domain binds CS and FH while the HMG domain binds HSPA8, bridging substrates to the CMA machinery for lysosomal degradation, thereby rewiring cancer cell metabolism toward aerobic glycolysis.

   Evidence Domain-truncation co-IP, lysosome/macroautophagy/proteasome inhibitor epistasis, CS/FH overexpression rescue, and metabolic flux assays in breast cancer cells

   PMID:36866961

   Open questions at the time

   • Whether LAMP2A (the CMA receptor) interaction is direct has not been shown
   • Structural basis for MAEL domain selectivity toward CS/FH over other mitochondrial enzymes is unknown
   • Single-lab finding awaits independent replication
10. 2023 Medium

    Demonstrating that MAEL localizes to sperm mitochondria and directly binds GPX4 and UBL4B, and that MAEL knockdown impairs mitochondrial function and ATP production, established a non-nuage mitochondrial role for MAEL in human spermatozoa.

    Evidence Immunogold staining of ejaculated human sperm, co-IP for GPX4 and UBL4B, siRNA knockdown with mitochondrial function and ATP assays in H358 cells

    PMID:36779514

    Open questions at the time

    • The functional consequence of MAEL–GPX4 binding (e.g., GPX4 stabilization or redox regulation) is not defined
    • Mitochondrial function assays were performed in a lung cancer cell line, not primary spermatozoa

• A unifying structural and mechanistic model explaining how MAEL's dual domains (MAEL and HMG) coordinate its diverse functions — transposon silencing, CMA scaffolding, Snail interaction, and mitochondrial roles — remains unresolved.
• No crystal or cryo-EM structure of MAEL exists
• Whether MAEL's germline piRNA function and its somatic CMA/degradation functions share a common biochemical mechanism is unknown
• In vivo conditional knockout models confirming cancer-specific MAEL functions are lacking